Triveni Bio secures $65M Series C as second eczema candidate enters clinical trials
read at Endpoints ↗DealPositive
Triveni Bio announced a $65 million Series C financing round aimed at supporting its ongoing development programs.
The round was co‑led by Ascenta Capital and Janus Henderson Investors, with participation from Deep Track and other investors.
The new capital comes as the company’s second eczema drug entered clinical studies last month, positioning it for upcoming readout milestones.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Triveni Bio raises $65M ahead of upcoming readouts on eczema drugs”
read at Endpoints ↗88 words · retrieved Jun 17
comments(0)
5-min edit window · permanent after that